CELONTIN Drug Patent Profile
✉ Email this page to a colleague
When do Celontin patents expire, and when can generic versions of Celontin launch?
Celontin is a drug marketed by Parke Davis and is included in one NDA.
The generic ingredient in CELONTIN is methsuximide. Two suppliers are listed for this compound. Additional details are available on the methsuximide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Celontin
A generic version of CELONTIN was approved as methsuximide by NOVITIUM PHARMA on May 1st, 2023.
Summary for CELONTIN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 67 |
| Patent Applications: | 2,935 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for CELONTIN |
| What excipients (inactive ingredients) are in CELONTIN? | CELONTIN excipients list |
| DailyMed Link: | CELONTIN at DailyMed |
Pharmacology for CELONTIN
| Drug Class | Anti-epileptic Agent |
| Physiological Effect | Decreased Central Nervous System Disorganized Electrical Activity |
US Patents and Regulatory Information for CELONTIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Parke Davis | CELONTIN | methsuximide | CAPSULE;ORAL | 010596-007 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Parke Davis | CELONTIN | methsuximide | CAPSULE;ORAL | 010596-008 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
